{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:37:15Z","timestamp":1787960235117,"version":"build-2784847793"},"reference-count":34,"publisher":"Georg Thieme Verlag KG","issue":"06","license":[{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>There has been limited evidence reported about the outcomes of oral anticoagulants among patients with venous thromboembolism (VTE) and chronic kidney disease (CKD), especially those with stage V\/end-stage renal disease (ESRD). This retrospective cohort analysis of five U.S. claims databases evaluated the risk of recurrent VTE, major bleeding (MB), and clinically relevant nonmajor bleeding (CRNMB) for apixaban versus warfarin among VTE patients diagnosed with CKD, including ESRD. Inverse probability treatment weighting (IPTW) was used to balance patient characteristics between treatment cohorts. Hazard ratios (HRs) were calculated for recurrent VTE, MB, and CRNMB among patients with CKD who experienced an index VTE. An interaction analysis was conducted to evaluate treatment effects across different stages of CKD. A total of 29,790 VTE patients with CKD were selected for analyses, of whom 10,669 (35.8%) initiated apixaban and 19,121 (64.2%) initiated warfarin. Among IPTW-balanced patient cohorts, the apixaban group had significantly lower risk of recurrent VTE (HR: 0.78; 95% confidence interval [CI]: 0.66\u20130.92), MB (HR: 0.76; 95% CI: 0.65\u20130.88), and CRNMB (HR: 0.86; 95% CI: 0.80\u20130.93) than the warfarin group. When stratified by CKD stage (stage I\/II: 8.2%; stage III: 49.4%; stage IV: 12.8%; stage V\/ESRD: 12.0%; stage unspecified: 17.6%), no significant interaction was observed for effects of apixaban versus warfarin on recurrent VTE or MB. In summary, apixaban was associated with a significantly lower risk of recurrent VTE and MB than warfarin among VTE patients with CKD. CKD stages did not have significant impact on treatment effects for recurrent VTE and MB.<\/jats:p>","DOI":"10.1055\/s-0041-1740254","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T19:05:39Z","timestamp":1640718339000},"page":"926-938","source":"Crossref","is-referenced-by-count":43,"title":["Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease"],"prefix":"10.1055","volume":"122","author":[{"given":"Alexander T.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Hematological Medicine, Guy's & St. Thomas' NHS Foundation Trust, King's College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janvi","family":"Sah","sequence":"additional","affiliation":[{"name":"SIMR, LLC, Ann Arbor, Michigan, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol D.","family":"Dhamane","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb Company, Lawrenceville, New Jersey, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Lee","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, New York, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Rosenblatt","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb Company, Lawrenceville, New Jersey, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hlavacek","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, New York, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birol","family":"Emir","sequence":"additional","affiliation":[{"name":"Pfizer Inc., New York, New York, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Delinger","sequence":"additional","affiliation":[{"name":"SIMR, LLC, Ann Arbor, Michigan, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huseyin","family":"Yuce","sequence":"additional","affiliation":[{"name":"Department of Mathematics, New York City College of Technology, City University of New York, New York, New York, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Luo","sequence":"additional","affiliation":[{"name":"Pfizer Inc., Groton, Connecticut, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,12,28]]},"reference":[{"issue":"05","key":"ref2","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1053\/j.ajkd.2011.06.021","article-title":"Venous thromboembolism in patients with reduced estimated GFR: a population-based perspective","volume":"58","author":"A M Parikh","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/j.ajkd.2016.10.039","article-title":"Measures of kidney disease and the risk of venous thromboembolism in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study","volume":"70","author":"K L Cheung","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"ref4","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1093\/ndt\/gfq179","article-title":"Chronic kidney disease and venous thromboembolism: a prospective study","volume":"25","author":"A R Folsom","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1681\/ASN.2007030308","article-title":"Chronic kidney disease increases risk for venous thromboembolism","volume":"19","author":"K Wattanakit","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.2215\/CJN.02170216","article-title":"Chronic kidney disease and risk for gastrointestinal bleeding in the community: the Atherosclerosis Risk in Communities (ARIC) study","volume":"11","author":"J Ishigami","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/jth.13904","article-title":"Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: a cohort study","volume":"16","author":"G Ocak","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1055\/s-2004-835678","article-title":"Platelet dysfunction in renal failure","volume":"30","author":"P Boccardo","year":"2004","journal-title":"Semin Thromb Hemost"},{"issue":"05","key":"ref9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/0002-9343(85)90051-8","article-title":"Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis","volume":"79","author":"G Di Minno","year":"1985","journal-title":"Am J Med"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"C Kearon","year":"2016","journal-title":"Chest"},{"issue":"19","key":"ref11","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"T L Ortel","year":"2020","journal-title":"Blood Adv"},{"issue":"09","key":"ref12","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"G Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"26","key":"ref13","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"R Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"issue":"15","key":"ref14","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"H R B\u00fcller","year":"2013","journal-title":"N Engl J Med"},{"issue":"24","key":"ref15","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"S Schulman","year":"2009","journal-title":"N Engl J Med"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/ajhp\/zxz307","article-title":"Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism","volume":"77","author":"G K Dawwas","year":"2020","journal-title":"Am J Health Syst Pharm"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/bloodadvances.2019000972","article-title":"Outcomes associated with apixaban vs warfarin in patients with renal dysfunction","volume":"4","author":"C Hanni","year":"2020","journal-title":"Blood Adv"},{"issue":"06","key":"ref18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/1060028020967635","article-title":"Direct oral anticoagulant use in chronic kidney disease and dialysis patients with venous thromboembolism: a systematic review of thrombosis and bleeding outcomes","volume":"55","author":"C YS Cheung","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"12","key":"ref20","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1097\/MLR.0000000000000524","article-title":"Validity of using inpatient and outpatient administrative codes to identify acute venous thromboembolism: the CVRN VTE study","volume":"55","author":"M C Fang","year":"2017","journal-title":"Med Care"},{"issue":"04","key":"ref21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.18553\/jmcp.2013.19.4.291","article-title":"One-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events","volume":"19","author":"S Y Chen","year":"2013","journal-title":"J Manag Care Pharm"},{"issue":"09","key":"ref22","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s12325-010-0056-z","article-title":"Warfarin therapy in patients with venous thromboembolism: patterns of use and predictors of clinical outcomes","volume":"27","author":"S B Deitelzweig","year":"2010","journal-title":"Adv Ther"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2215\/CJN.04230510","article-title":"Development and validation of an electronic health record-based chronic kidney disease registry","volume":"6","author":"S D Navaneethan","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12882-019-1429-4","article-title":"Can billing codes accurately identify rapidly progressing stage 3 and stage 4 chronic kidney disease patients: a diagnostic test study","volume":"20","author":"K Jalal","year":"2019","journal-title":"BMC Nephrol"},{"issue":"11","key":"ref25","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1055\/s-0038-1673689","article-title":"Effectiveness and safety of apixaban versus warfarin as outpatient treatment of venous thromboembolism in U.S. clinical practice","volume":"118","author":"D Weycker","year":"2018","journal-title":"Thromb Haemost"},{"issue":"12","key":"ref26","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1080\/03007995.2019.1653067","article-title":"Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population","volume":"35","author":"P Hlavacek","year":"2019","journal-title":"Curr Med Res Opin"},{"issue":"02","key":"ref27","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1182\/bloodadvances.2019001081","article-title":"Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses","volume":"4","author":"D Weycker","year":"2020","journal-title":"Blood Adv"},{"issue":"03","key":"ref28","first-page":"383","article-title":"Effectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer: a U.S. claims data analysis","volume":"121","author":"A T Cohen","year":"2020","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref29","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/pds.2109","article-title":"An automated database case definition for serious bleeding related to oral anticoagulant use","volume":"20","author":"A Cunningham","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"ref30","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"S Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref31","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/jth.13336","article-title":"Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH","volume":"14","author":"C Kearon","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref32","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"P C Austin","year":"2014","journal-title":"Stat Med"},{"issue":"28","key":"ref33","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"P C Austin","year":"2015","journal-title":"Stat Med"},{"issue":"01","key":"ref34","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/2167696815621645","article-title":"A primer on inverse probability of treatment weighting and marginal structural models","volume":"4","author":"F Thoemmes","year":"2016","journal-title":"Emerg Adulthood"},{"issue":"02","key":"ref35","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","article-title":"Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals","volume":"13","author":"S Xu","year":"2010","journal-title":"Value Health"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1053\/j.ajkd.2005.04.029","article-title":"Identification of individuals with CKD from Medicare claims data: a validation study","volume":"46","author":"W C Winkelmayer","year":"2005","journal-title":"Am J Kidney Dis"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0041-1740254.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T18:48:30Z","timestamp":1656960510000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0041-1740254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,28]]},"references-count":34,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2022,7,4]]},"published-print":{"date-parts":[[2022,6]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0041-1740254","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,28]]}}}